New trends in advanced parkinson disease stage therapy
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
The aim of the study was to point out the contribution of new invasive therapeutic procedures in the treatment of advanced stages of Parkinson's disease (PD) in comparison with classical oral pharmacotherapy. Data originated from a group of 43 patients with PD, 39% (17) with classic treatment, 23% (10) with intestinal gel of methyl ester levodopa (Duodopa), 19% (8) of patients were using subcutaneous delivery of apomorphine (APO) and the same quantity of patients had undergone deep brain stimulation (DBS). Majority of patients had advanced stages of PD, stage 4, by standards of Hoehn and Yahr scale (Hoehn and Yahr, 1967). Research observed improvement in majority of patients with novel treatments. A positive effect was also noted in the reduced need for oral therapy, where there was a significant decrease in all new therapies. Benefits were observed in the amount of antiparkinsonic drugs taken per os, where we observed reduction in all new therapies. A positive effect of the new therapeutic approaches in reducing "off" periods in patients has also been noted. In the case of Duodopa and DBS, the "off" period was shortened up to 50% and in the apomorphine pump up to 40%. Patients also reported reduction of some symptoms like rigidity, tremor and bradykinesis while dyskinesis still remains suba challenge. On the basis of the obtained results, it can be concluded that new therapeutic procedures for PCh will make it possible to manage symptoms typical of advanced stages of the disease, which without these procedures would lead to disability, which is the main reason for their indication. However, in early stages, well responding patients or in slow progressing disease oral antiparkinsonics are remaining as golden standard of treatment. This is not just due to good response but also because these classic drug formulations are significantly less expensive. In Slovakia, novel treatments are accessible through healthcare insurance only after secondary revision by insurance company doctors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720
Non-motor symptoms of Parkinson's disease: diagnosis and management
Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70373-8 · Cited by 2,807
Aromatic Amino Acids and Modification of Parkinsonism
Cotzias, G. C., Van Woert, M. H., & Schiffer, L. M. (1967) · New England Journal of Medicine · doi:10.1056/nejm196702162760703 · Cited by 1,494
Ahlskog, J. E., & Muenter, M. D. (2001) · Movement Disorders · doi:10.1002/mds.1090 · Cited by 1,454
Fox, S. H., Katzenschlager, R., Lim, S., Ravina, B., Seppi, K., Coelho, M., Poewe, W., Rascol, O., Goetz, C. G., & Sampaio, C. (2011) · Movement Disorders · doi:10.1002/mds.23829 · Cited by 523
Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics
LeWitt, P. A. (2015) · Movement Disorders · doi:10.1002/mds.26082 · Cited by 391
Nonmotor fluctuations in Parkinson disease: Severity and correlation with motor complications
Storch, A., Schneider, C. B., Wolz, M., Stürwald, Y., Nebe, A., Odin, P., Mahler, A., Fuchs, G., Jost, W. H., Chaudhuri, K. R., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e318285c0ed · Cited by 372
Re-evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states
Levy, R., Hazrati, L.-N., Herrero, M.-T., Vila, M., Hassani, O.-K., Mouroux, M., Ruberg, M., Asensi, H., Agid, Y., Féger, J., et al. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00409-5 · Cited by 271
Pedunculopontine nucleus deep brain stimulation in Parkinson's disease: A clinical review
Thevathasan, W., Debu, B., Aziz, T., Bloem, B. R., Blahak, C., Butson, C., Czernecki, V., Foltynie, T., Fraix, V., Grabli, D., et al. (2018) · Movement Disorders · doi:10.1002/mds.27098 · Cited by 228
Combs, H. L., Folley, B. S., Berry, D. T. R., Segerstrom, S. C., Han, D. Y., Anderson-Mooney, A. J., Walls, B. D., & van Horne, C. (2015) · Neuropsychology Review · doi:10.1007/s11065-015-9302-0 · Cited by 205
Loher, T. J. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.73.4.395 · Cited by 125
Lee, P., Liu, L.-L., Sun, Y., Chen, Y., Liu, C., Li, C., Yu, H., & Ritz, B. R. (2016) · Environment International · doi:10.1016/j.envint.2016.08.017 · Cited by 123
Levodopa–Carbidopa Intestinal Gel in Patients with Parkinson’s Disease: A Systematic Review
Wirdefeldt, K., Odin, P., & Nyholm, D. (2016) · CNS Drugs · doi:10.1007/s40263-016-0336-5 · Cited by 109
Kaňovský, P., Kubová, D., Bareš, M., Hortová, H., Streitová, H., Rektor, I., & Znojil, V. (2002) · Movement Disorders · doi:10.1002/mds.1276 · Cited by 100
Katzenschlager, R., Poewe, W. H., Rascol, O., Trenkwalder, C., Deuschl, G., Chaudhuri, К. R., Henriksen, T., van Laar, T., Lockhart, D., Staines, H., et al. (2021) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.12.024 · Cited by 94
Psychogenic Movement Disorders
Fahn, S., Jankovic, J. J., Hallett, M., & Jenner, P. G. (2007) · Elsevier eBooks · doi:10.1016/b978-0-443-07941-2.50029-2 · Cited by 46
Apomorphine in the treatment of Parkinson's disease: a review
Pessoa, R. R., Moro, A., Munhoz, R. P., Teive, H. A. G., & Lees, A. J. (2018) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20180140 · Cited by 44
Amantadine infusion in treatment of motor fluctuations and dyskinesias in Parkinson's disease
Růžička, E., Streitová, H., Jech, R., Kaňovský, P., Roth, J., Rektorová, I., Mečíř, P., Hortová, H., Bareš, M., Hejduková, B., et al. (2000) · Journal of Neural Transmission · doi:10.1007/s007020070019 · Cited by 41
Levodopa/Carbidopa Enteral Suspension: A Review in Advanced Parkinson’s Disease
Hoy, S. M. (2019) · Drugs · doi:10.1007/s40265-019-01201-1 · Cited by 20
Hluboká mozková stimulace u Parkinsonovy nemoci
Baláž, M. (2013) · Neurologie pro praxi · Cited by 6
Farmakoterapie pokročilé Parkinsonovy nemoci ve světle doporučených postupů
Kaňovský, P., & Farníková, M. K. (2010) · Neurologie pro praxi · Cited by 3
Invasive Methods in the Treatment of Advanced Parkinson’s Disease
Gmitterová, K., Minár, M., Košutzská, Z., & Valkovič, P. (2017) · Česká a slovenská neurologie a neurochirurgie · doi:10.14735/amcsnn2017503 · Cited by 3
Dlouhodobá terapie intraduodenální levodopou - kazuistiky tří pacientů
Baláž, M., Kianička, B., & Bareš, M. (2014) · Neurologie pro praxi · Cited by 1
Terapie Parkinsonovy nemoci levodopou v kontinuální enterální infuzi
Klempíř, J., Havránková, P., & Jech, R. (2015) · Neurologie pro praxi · Cited by 1
Research works printed but not linked: 6
- Švihovec, 2018, a kol. Farmakologie
- 2004, Růžička E., Urgošík D., Jech R., Serranová T., Volfová M., Roth J., Vymazal J., Mečíř P., Nováková L., Nováková O., Ulmanová O., Brožová H., Dušek P., Špačková N., Liščák R., Vladyka V. Hluboká mozková stimulace v léčbě Parkinsonovy nemoci a třesu: Pražská zkušenost 1998-2003. Čes, Slov. Neurol. N, 67, 423
- Valkovič, 2006, Súčasný pohľad na Parkinsonovu chorobu, Via pract, 3, 256
- Richter, 2011, Súčasný pohľad na liečbu Parkinsonovej choroby, Edukafarm MediNews, 1, 37
- 2020, Karadağ Y. S., Saltoğlu T., Küçükdağli F. E., Öztürk Ö., Köseoğlu H. T., Altiparmak E. Comprehensive assessment od levodopa-carbidopa intestinal gef for Turkish advanced Parkinson's disease patients, Turkish Journal of Medical Sciences, 51, 84
- Bohušová, 2020, Analýza vplyvu antiparkinsoník na poruchy kontroly impulzov zisťovaných pomocou metódy samohodnotenia pacientmi, Folia Pharmaceutica cassoviensia, II, 7
Cited by
Pereira, C. R., Machado, J., Criado, B., Santos, R., Reis, A. M., Ramos, B., Santos, M. J., & Greten, H. J. (2025) · Clinical Parkinsonism & Related Disorders · doi:10.1016/j.prdoa.2025.100324 · Cited by 1
Acupuncture Effect on Reaction-Time Changes in Parkinson’s Disease Patients—Case Study Series
Pereira, C. R., Greten, H. J., Santos, R. S., Reis, A. M., Ramos, B., Santos, M. J., Machado, J. P., & Criado, M. B. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13185642 · Cited by 1
Metadata
- Authors
- Kolesárová, M., Franko, O., Kolesár, D., Gažová, A., & Kyselovič, J.
- Venue
- Česká a slovenská farmacie
- Publisher
- Solen s.r.o.
- Published
- 2023-01-01
- Volume
- 72
- Issue
- 1
- Pages
- 37-44
- ISSN
- 1210-7816 (ISSN-L)
- 1805-4439
- OpenAlex
- W4322757328
- Cited by
- 2
- References
- 25
- Citations by year
- 2025: 1 · 2024: 1
- FWCI
- 0.34
- Type
- journal article
- Language
- cs
- Open access
- hybrid
- doi.org
- Locations
- Česká a slovenská farmacie (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- advanced Parkinson's disease, deep brain stimulation, Duodopa, off periods, Hoehn and Yahr stage, dyskinesia, treatment costs, insurance coverage
- MeSH terms
- Administration, Oral, Apomorphine, Esters, Humans, Parkinson Disease, Slovakia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.